The heavy selling pressure might have exhausted for Soleno Therapeutics (SLNO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

Soleno Therapeutics ( ($SLNO) ) has issued an announcement. During August 18-19, 2025, Soleno Therapeutics‘ senior management participated in a ...

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a Buy rating on the shares. The firm says ...

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...

Scorpion Capital disclosed a short position in Soleno Therapeutics on Friday, citing issues with the drugmaker's recently approved treatment Vykat XR, sending its shares slumping 15% in premarket ...

View the latest Soleno Therapeutics Inc. (SLNO) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Soleno Therapeutics (SLNO) dropped 16% in premarket trading after a new short report from Scorpion Capital. Scorpion Capital ...

Soleno Therapeutics (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases ...

Discover key insights from Soleno Therapeutics' Q2 2025 earnings call, highlighting Vykat XR's strong launch, revenue growth, EU expansion efforts & ...

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM ...

Analysts are estimating that Soleno Therapeutics will report an earnings per share (EPS) of $-0.53. The market awaits Soleno ...